Browsing Tag
ALK+ NSCLC
1 post
FDA accelerates review of Novartis’s Zykadia for first-line treatment in lung cancer
Novartis AG, a prominent Swiss pharmaceutical company, has received a significant regulatory boost as its lung cancer medication,…